

**Prior Authorization (PA) Form: Hereditary Angioedema (HAE) Medications**

HealthKeepers, Inc. | Anthem HealthKeepers Plus Medicaid products

If the following information is not complete, correct, or legible, the PA process can be delayed .  
 Please use one form per member.

**Member information**

**Last name:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**First name:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Medicaid ID number:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Date of birth:**

				-					-				
--	--	--	--	---	--	--	--	--	---	--	--	--	--

**Gender:**  Male  Female

**Weight in kilograms:** \_\_\_\_\_

**Prescriber information**

**Last name:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**First name:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**NPI number:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Phone number:**

				-					-				
--	--	--	--	---	--	--	--	--	---	--	--	--	--

**Fax number:**

				-					-				
--	--	--	--	---	--	--	--	--	---	--	--	--	--

**Drug information**

**Preferred medications (quantity limits):**

- Cinryze™** – 20 vials per 34 days  **Berinert®** – 4 vials per attack (plus 4 for emergency)  
 **icatibant:** 1 dose per attack (plus 1 for emergency)  **Sajazir™:** 1 dose per attack (plus 1 for emergency)  
 **Kalbitor®** – 3 vials per attack (plus 3 for emergency) (see Black Box warning below)

**Because of the risk of anaphylaxis, KALBITOR® should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema.**

**Non-preferred Medications (Quantity Limits):**

- Firazyr®:** 1 dose per attack (plus 1 for emergency)  **Orladeyo™:** 34 capsules per 34 days  
 **Ruconest®:** 2 vials per attack (plus 2 for emergency)  **Takhzyro®:** 2 vials per 28 days  
 **Haegarda®:** 2,000 IU SDV kit (16 kits per 28 days) and 3,000 IU SDV kit (8 kits per 28 days)

**Drug Name/Form:** \_\_\_\_\_

**Strength:** \_\_\_\_\_

**Dosing Frequency:** \_\_\_\_\_

**Length of Therapy:** \_\_\_\_\_

**Quantity per Day:** \_\_\_\_\_

(Form continued on next page.)

Member's last name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Member's first name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Diagnosis and medical information**

---

1. Has the recipient's diagnosis of HAE been confirmed by C1 inhibitor (C1-INh) deficiency or dysfunction (type I or II HAE) as documented by one of the following:

- C1-INh antigenic level below the lower limit of normal; **or**
- C1-INh functional level below the lower limit of normal?

Yes     No

2. Was the medication prescribed by, or in consultation with, a specialist in allergy, immunology, hematology, pulmonology, or medical genetics?

Yes     No

**TREATMENT OF ACUTE HAE ATTACKS**

Berinert® (C1 esterase inhibitor), Firazyr® (icatibant), icatibant, Kalbitor® (ecallantide), Ruconest® (C1 esterase inhibitor), Sajazir™(icatibant)

1. Will the requested medication be used as mono therapy to treat acute HAE attacks?

Yes     No

**PROPHYLAXIS OF HAE ATTACKS**

Cinryze® (C1 esterase inhibitor), Haegarda® (C1 esterase inhibitor), Orladeyo® (berotralstat), Takhzyro® (ianadelumab-flyo)

1. Will the requested medication be used for prophylaxis of HAE attacks?

Yes     No

---

**Prescriber Signature (Required)**

**Date**

By signature, the physician confirms the above information is accurate and verifiable by member records.

**Please include all requested information; Incomplete forms will delay the PA process.**

Submission of documentation does **not** guarantee coverage.

The completed form may be **faxed to 844-512-7020**.